Xiao Min Schebye, San Carlos, CA (US); Mark J. Selby, San Francisco, CA (US); Michelle Minhua Han, Piedmont, CA (US); Christine Bee, San Francisco, CA (US); Andy X. Deng, San Mateo, CA (US); Anan Chuntharapai, Daly City, CA (US); Brigitte Devaux, Palo Alto, CA (US); Huiming Li, Lexington, MA (US); Paul O. Sheppard, Granite Falls, WA (US); Alan J. Korman, Piedmont, CA (US); Daniel F. Ardourel, Woodinville, WA (US); Ekaterina Deyanova, Lawrenceville, NJ (US); Richard Huang, Bridgewater, NJ (US); Guodong Chen, East Brunswick, NJ (US); Michelle Kuhne, San Francisco, CA (US); and Hong-An Truong, San Francisco, CA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Feb. 27, 2023, as Appl. No. 18/175,420.
Application 18/175,420 is a continuation of application No. 16/697,653, filed on Nov. 27, 2019, granted, now 11,591,392.
Application 16/697,653 is a continuation of application No. 16/017,489, filed on Jun. 25, 2018, granted, now 10,533,052, issued on Jan. 14, 2020.
Application 16/017,489 is a continuation of application No. 15/649,380, filed on Jul. 13, 2017, granted, now 10,077,306, issued on Sep. 18, 2018.
Claims priority of provisional application 62/459,499, filed on Feb. 15, 2017.
Claims priority of provisional application 62/362,541, filed on Jul. 14, 2016.
Prior Publication US 2023/0382992 A1, Nov. 30, 2023
1. A method of stimulating an immune response in a subject, comprising administering to the subject an antibody that binds to human T-cell immunoglobulin and mucin-domain containing-3 (TIM3), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 41, 122, and 126, respectively, and the VL comprises a light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 64, 66, and 68, respectively.